CompletedNot Applicable

Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes

Japan1,595 participantsStarted 2015-07-07

Plain-language summary

The objective of this investigation is to collect following data in patients given NEXIUM capsule (NEXIUM) in usual post-marketing use.

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Aged at least 20 years.
✓. Patients who has a current or past history of clinically diagnosed RE
✓. Patients whose answers in the baseline GerdQ include "2-3 days" or "4-7 days" in at least one of the questions Nos 1, 2, 5 and 6.
✓. Patients to whom NEXIUM 20 mg once daily is to be administered for RE
✓. Patients from whom written consent has been obtained.

✕. Patients whose ability to follow instructions are suspected to be low by physicians
✕. Patients with a past history of hypersensitivity to the ingredients of NEXIUM.
✕. Patients receiving atazanavir sulfate or rilpivirine hydrochloride
✕. Patients who have received NEXIUM within the past eight weeks for treatment of RE

Treatment response to NEXIUM based on answers in GerdQ

Timeframe: at the time of Treatment Week 8

NCT IDNCT02477475

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2017-02-20